Companies › Zero Point Five Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ZP5-9676 Broad-spectrum benzimidazole anthelmintic | Tubulin | Phase 3 | Soil-Transmitted Helminthiasis (STH) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06128447 | ZP5-9676 | Phase 3 | Soil-Transmitted Helminthiasis (STH) | Infectious disease | Mar 2027 |
Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Beijing Biostar Pharmaceuticals Urotronic
Laboratorio Farmaceutico SIT srl Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx Jiangxi Qingfeng Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.